Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

References

• Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics. 2016;17(11):1245–1272.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Martínez-Cuadrón D, Herrero MJ, et al. Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia. Curr Drug Metab. 2018;19(1):55–74.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Candoni A, et al. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J. 2012;13:335–341.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Jada SR, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007;8(6):567–575.
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010;102:1003–1009.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Rojas L, Herrero MJ, et al. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:109–118.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Rojas L, Herrero MJ, et al. Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. Pharmacogenomics J. 2015;16:1–2.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2017;58(5):1197–1206.
   PubMed Web of Science ®Google Scholar
• Hampras SS, Sucheston L, Weiss J, et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. Int J Mol Epidemiol Genet. 2010;1:201–207.
   PubMedGoogle Scholar
• Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422–1428.
   PubMed Web of Science ®Google Scholar
• Yee SW, Mefford JA, Singh N, et al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013;58:353–361.
   PubMed Web of Science ®Google Scholar
• Müller P, Asher N, Heled M, et al. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res. 2008;32:919–929.
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Fabbro D, Franzoni A, et al. Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. Haematologica. 2013;98:e28–e29.
   PubMedGoogle Scholar
• Wang F, Liang YJ, Wu XP, et al. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer. 2011;47(13):1990–1999.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876, younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Colovic N, Tomin D, Vidovic A, et al. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. Biomed Pharmacother. 2012;66:578–582.
   PubMed Web of Science ®Google Scholar
• Olivera GG, Yáñez Y, Gargallo P, et al. MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. IJMS. 2020;21(8):2714.
   Web of Science ®Google Scholar
• Oshiro C, Mangravite L, Klein T, et al. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20(3):211–216.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–181.
   PubMed Web of Science ®Google Scholar
• Drenberg CD, Paugh SW, Pounds SB, et al. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. 2016;99:651–660.
   PubMed Web of Science ®Google Scholar
• Durmus S, Naik J, Buil L, et al. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. Int J Cancer. 2014;135:1700–1710.
   PubMed Web of Science ®Google Scholar
• Kim KI, Huh IS, Kim IW, et al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer. 2013;49(2):403–410.
   PubMed Web of Science ®Google Scholar
• Wan H, Zhu J, Chen F, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33:90.
   PubMed Web of Science ®Google Scholar
• Strom SS, Estey E, Outschoorn UM, et al. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Leuk Lymphoma. 2010;51:598–605.
   PubMed Web of Science ®Google Scholar
• Rhodes KE, Zhang W, Yang D, et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007;1:23–30.
   PubMedGoogle Scholar
• Sai K, Saito Y, Maekawa K, et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 2010;66:95–105.
   PubMed Web of Science ®Google Scholar
• Peters BJ, Rodin AS, Klungel OH, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics. 2010;11:1065–1076.
   PubMed Web of Science ®Google Scholar
• Neve EP, Artursson P, Ingelman-Sundberg M, et al. An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. Mol Pharm. 2013;10:3152–3163.
   PubMed Web of Science ®Google Scholar
• Lane HY, Tsai GE, Lin E. Assessing gene-gene interactions in pharmacogenomics. Mol Diagn Ther. 2012;16:15–27.
   PubMed Web of Science ®Google Scholar
• Valcárcel D, Montesinos P, Sánchez-Ortega I, et al. CETLAM Group. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer. 2012;118(2):410–417.
   PubMed Web of Science ®Google Scholar
• Lahoti A, Kantarjian H, Salahudeen AK, et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010;116:4063–4068.
   PubMed Web of Science ®Google Scholar
• Amaki J, Onizuka M, Ohmachi K, et al. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015; 101:543–553.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wan L, Han Y, et al. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. Pharm Biol. 2013;51:968–973.
   PubMed Web of Science ®Google Scholar